MYR GmbH
Description: MYR is a German biotech firm that developed HepcludexTM, a first-in-class treatment for chronic hepatitis D (HDV).
Country: Germany
Based in: Bad Homburg
Founded: 2011
Funding Stage: Series C & Beyond
Tags: ['Biotechnology', 'Health Care', 'Pharmaceutical']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
